Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

BACKGROUND: We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults. METHODS: We did a randomised, double-blind, placebo-controlled, mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ella, Raches, Reddy, Siddarth, Blackwelder, William, Potdar, Varsha, Yadav, Pragya, Sarangi, Vamshi, Aileni, Vinay K, Kanungo, Suman, Rai, Sanjay, Reddy, Prabhakar, Verma, Savita, Singh, Chandramani, Redkar, Sagar, Mohapatra, Satyajit, Pandey, Anil, Ranganadin, Pajanivel, Gumashta, Raghavendra, Multani, Manish, Mohammad, Shameem, Bhatt, Parul, Kumari, Laxmi, Sapkal, Gajanan, Gupta, Nivedita, Abraham, Priya, Panda, Samiran, Prasad, Sai, Bhargava, Balram, Ella, Krishna, Vadrevu, Krishna Mohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584828/
https://www.ncbi.nlm.nih.gov/pubmed/34774196
http://dx.doi.org/10.1016/S0140-6736(21)02000-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584828/
https://www.ncbi.nlm.nih.gov/pubmed/34774196
http://dx.doi.org/10.1016/S0140-6736(21)02000-6

Ejemplares similares